Development of the Effectiveness of Rehabilitation Tools for Neurovisual Disorders in Patients With Posterior Cortical Atrophy

Development and Evaluation of the Effectiveness of Rehabilitation Tools for Neurovisual Disorders in Patients With Posterior Cortical Atrophy (PCA)

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04041089

Acronym

REEDUC-ACP

Enrollment

Registered

2019-08-01

Start date

2019-09-02

Completion date

2022-06-15

Last updated

2023-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Posterior Cortical Atrophy

Brief summary

Posterior cortical atrophy (PCA) is manifested by neuro-visual disorders that alter the spatial location of objects, their manipulation and/or recognition. Its etiology is most often neurodegenerative, with a major impact on the autonomy and mood of patients and their families. Few studies have focused on non-medication management of these disorders. The present study thus has a double objective: the development of a complete tool to work on the recognition, localization and/or manipulation of objects; and the evaluation of the effectiveness of this type of management.

Interventions

BEHAVIORALRecognition of objects

* Name of shapes / colors / images / objects * Classification of shapes / colors / images / objects

BEHAVIORALLocation of objects

* Search for frequent/rarse targets among distractors sharing one or more characteristics with the target * Hit/catch a stationary/mobile target as quickly as possible

BEHAVIORALManipulation of objects

* Storage of shapes/objects * Use of everyday objects (pen, cutlery, etc.)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \>50 years old * Male or Female * Patients with a diagnosis of PCA according to the criteria of Tang-Wai et al (2004) * MMS\>15 * Voluntary, written and informed consent of the patient himself or its legal representative (guardian/curator), with oral consent of the patient in all cases * Anti-Alzheimer's and psychotropic treatments stable for one month, if taken by the patient * Affiliation to a social security system

Exclusion criteria

* Uncorrected visual disorders with non-degenerative etiology (AV\<0.5) * Person under the protection of justice * Pregnant women (a pregnancy test will be performed in premenopausal women)

Design outcomes

Primary

Measure	Time frame	Description
Effectiveness evaluation	At week 34	Effectiveness will be evaluated a score based on success rate (from 0 to 10), reaction time and eye-recording .

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026